Maze Therapeutics Inc.

$MAZE results for their experimental treatment for a rare, genetic disease blew past the company’s own expectations and as a result shares are making new all-time highs. The treatment is for phenylketonuria, or PKU, a condition in which the body can’t break down phenylalanine, an essential amino acid. The buildup of phenylalanine can lead to intellectual disability, seizures, small head size, skin and hair problems, and behavioral issues.